BIBF 1120 and angiogenesis inhibition Carlos Gil Ferreira
BIBF 1120* Mode of Action
BIBF 1120 in ovarian cancer Keiichi Fujiwara
BIBF 1120 (Vargatef) in lung cancer Lucio Crinò
The latest data for BIBF 1120* in ovarian cancer Marianne Nicolson
Angiokinase inhibitors in lung cancer Marianne Nicolson
LUME-Ovar 1 ovarian cancer clinical trial Eric Pujade-Lauraine
Targeted cancer therapies
Angiokinase Inhibition and Nintedanib (BIBF 1120)*
LUME Lung 2 clinical trial infographic
LUME-Lung 1 Infographic
BIBF 1120 anticancer agent
Mode of Action BIBF 1120* slide kit
Tumour growth and angiogenesis
Tumour angiogenesis and apoptosis
Tumour angiogenesis in lung cancer
Clinical trials data suggests promising overall survival and progression-free survival in patients with NSCLC using BIBF 1120*
Press release LUME-Ovar 1 December 2009
Press release LUME-Lung 1+2 November 2008
Lume lung 1 cancer clinical trial
Lume lung 2 cancer clinical trial
Boehringer Ingelheim to present new data on two lead oncology compounds at ASCO 2009
Webcast South Korea, the evolution of lung cancer care
BIBF 1120 (Vargatef) slide kit
LUME Ovar clinical trial overview
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.